2296729-00-3 Usage
Description
(1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one is a complex organic compound with a unique molecular structure. It is characterized by its chiral center at the 1R position and the presence of various functional groups, including fluoro, hydroxy, and pyridinyl moieties. (1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one belongs to a class of molecules known as pyrido[2,3-d]pyrimidines, which have been explored for their potential biological activities and applications in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
(1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one is used as an antineoplastic agent for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. Its application is based on its ability to act as a potent KRAS G12C covalent inhibitor, which has demonstrated antitumor activity in clinical trials.
Used in Drug Development:
(1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one is also used in the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles have been explored as carriers for this compound, aiming to improve its delivery, bioavailability, and therapeutic outcomes.
Side effects
Sotorasib may cause breathing problems that could lead to death. Get emergency medical help if you have new or worsening fever, cough, or shortness of breath.Common side effects may include:nausea, diarrhea;cough;liver problems;pain in your bones, joints, or muscles;tiredness;abnormal lab tests.For 28 patients (22%), side effects led to a pause, a reduction, or both, in the dose of sotorasib. Nine people (7%) stopped the treatment because of side effects.www.everydayhealth.com/drugs/sotorasib
Mode of action
Sotorasib is an orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.
Check Digit Verification of cas no
The CAS Registry Mumber 2296729-00-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,2,9,6,7,2 and 9 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2296729-00:
(9*2)+(8*2)+(7*9)+(6*6)+(5*7)+(4*2)+(3*9)+(2*0)+(1*0)=203
203 % 10 = 3
So 2296729-00-3 is a valid CAS Registry Number.
2296729-00-3Relevant articles and documents
IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND
-
Paragraph 0125; 0142-0146, (2021/05/21)
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
-
Page/Page column 55; 68-69, (2020/06/05)
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure (I), useful for the synthesis of compounds that target KRAS G12C mutations, such as (II).
COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
-
Page/Page column 82; 93-94, (2020/06/10)
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as (see Formula), or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
